Delcath Systems (DCTH) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Delcath Systems (DCTH) has outperformed TransMedics Group (TMDX) over the past year, gaining 42.4% versus a loss of 33.1%. Over five years, TMDX leads with a +197.6% price change compared with +63.4% for DCTH. TransMedics Group is the larger company by market cap ($2.74 billion vs $521.9 million), about 5.2 times the size.
On valuation, TransMedics Group trades at a lower forward P/E (35.0x vs 334.2x for Delcath Systems).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | TMDX |
|---|---|---|
| Share price | $15.04 | $79.00 |
| Market cap | $521.87M | $2.74B |
| 1-day change | -2.21% | -2.55% |
| YTD return | +52.28% | -35.06% |
| 1-year return | +42.41% | -33.08% |
| 5-year return | +63.44% | +197.55% |
| P/E ratio (TTM) | — | 20.47 |
| Forward P/E | 334.22 | 35.05 |
| EPS (TTM) | $0.01 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $605.49M |
| Revenue growth (YoY) | — | +37.13% |
| Net income (latest FY) | — | $190.29M |
| Gross margin | — | 59.92% |
| Operating margin | — | 17.93% |
| Net margin | — | 31.43% |
| 52-week high | $17.42 | $156.00 |
| 52-week low | $8.12 | $60.11 |
| Distance from 52-week high | -13.66% | -49.36% |
| Analyst consensus | none | buy |
| Avg. price target upside | +59.57% | +26.35% |
| Average volume | 479.73K | 820.41K |
| Shares outstanding | 34.70M | 34.68M |
| Employees | 156 | 898 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TransMedics Group is about 5.2 times larger than Delcath Systems by market value ($2.74B vs $521.87M).
- DCTH has outperformed TMDX by 75.5 percentage points over the past year.
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Healthcare · Medical Devices · 156 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Healthcare · Medical Devices · 898 employees
DCTH vs TMDX FAQ
Which is bigger, Delcath Systems or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.74B compared with $521.87M for Delcath Systems (DCTH).
Which stock has performed better over the past year, DCTH or TMDX?
DCTH returned +42.41% over the past 12 months, compared with -33.08% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Are Delcath Systems and TransMedics Group in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.